P Marteau

Summary

Country: France

Publications

  1. ncbi Inflammatory bowel disease
    P Marteau
    Department of Gastroenterology, Hopital Europeen Georges Pompidou, Assistance Publique des Hopitaux de Paris, and Paris V University, France
    Endoscopy 34:63-8. 2002
  2. ncbi Reduced diversity of faecal microbiota in Crohn's disease revealed by a metagenomic approach
    C Manichanh
    , INRA-UEPSD, 78350 Jouy-en-Josas, France
    Gut 55:205-11. 2006
  3. ncbi Low counts of Faecalibacterium prausnitzii in colitis microbiota
    H Sokol
    UEPSD, INRA, Jouy en Josas, France
    Inflamm Bowel Dis 15:1183-9. 2009
  4. ncbi Combined oral and enema treatment with Pentasa (mesalazine) is superior to oral therapy alone in patients with extensive mild/moderate active ulcerative colitis: a randomised, double blind, placebo controlled study
    P Marteau
    Gastroenterology, Hopital Europeen Georges Pompidou, 20 rue Leblanc, 75908 Paris Cedex 15, France
    Gut 54:960-5. 2005
  5. ncbi Search for localized dysbiosis in Crohn's disease ulcerations by temporal temperature gradient gel electrophoresis of 16S rRNA
    Philippe Seksik
    INRA, CR de Jouy en Josas, France
    J Clin Microbiol 43:4654-8. 2005
  6. ncbi Ineffectiveness of Lactobacillus johnsonii LA1 for prophylaxis of postoperative recurrence in Crohn's disease: a randomised, double blind, placebo controlled GETAID trial
    P Marteau
    Department Gastroenterology, Hopital Europeen Georges Pompidou, Paris, France
    Gut 55:842-7. 2006
  7. ncbi Temperature gradient gel electrophoresis of fecal 16S rRNA reveals active Escherichia coli in the microbiota of patients with ulcerative colitis
    H Sokol
    INRA, UEPSD, CR de Jouy-en-Josas, 78352 Jouy-en-Josas, France
    J Clin Microbiol 44:3172-7. 2006
  8. ncbi Alterations of the dominant faecal bacterial groups in patients with Crohn's disease of the colon
    P Seksik
    INRA, CR de Jouy-en-Josas, 78352 Jouy en Josas, France
    Gut 52:237-42. 2003
  9. ncbi Review article: gut flora and inflammatory bowel disease
    P Marteau
    Département d Hépato Gastroentérologie, Hopital Europeen Georges Pompidou, Paris, France
    Aliment Pharmacol Ther 20:18-23. 2004
  10. ncbi Infliximab for refractory ulcerative colitis or indeterminate colitis: an open-label multicentre study
    J M Gornet
    Department of Gastroenterology, Hopital Saint Louis, Paris, France
    Aliment Pharmacol Ther 18:175-81. 2003

Collaborators

Detail Information

Publications38

  1. ncbi Inflammatory bowel disease
    P Marteau
    Department of Gastroenterology, Hopital Europeen Georges Pompidou, Assistance Publique des Hopitaux de Paris, and Paris V University, France
    Endoscopy 34:63-8. 2002
    ....
  2. ncbi Reduced diversity of faecal microbiota in Crohn's disease revealed by a metagenomic approach
    C Manichanh
    , INRA-UEPSD, 78350 Jouy-en-Josas, France
    Gut 55:205-11. 2006
    ..02). CONCLUSION: The metagenomic approach allowed us to detect a reduced complexity of the bacterial phylum Firmicutes as a signature of the faecal microbiota in patients with CD. It also indicated the presence of new bacterial species...
  3. ncbi Low counts of Faecalibacterium prausnitzii in colitis microbiota
    H Sokol
    UEPSD, INRA, Jouy en Josas, France
    Inflamm Bowel Dis 15:1183-9. 2009
    ..The aim was to compare the fecal microbiota composition of patients with colitis to that of healthy subjects (HS)...
  4. ncbi Combined oral and enema treatment with Pentasa (mesalazine) is superior to oral therapy alone in patients with extensive mild/moderate active ulcerative colitis: a randomised, double blind, placebo controlled study
    P Marteau
    Gastroenterology, Hopital Europeen Georges Pompidou, 20 rue Leblanc, 75908 Paris Cedex 15, France
    Gut 54:960-5. 2005
    ....
  5. ncbi Search for localized dysbiosis in Crohn's disease ulcerations by temporal temperature gradient gel electrophoresis of 16S rRNA
    Philippe Seksik
    INRA, CR de Jouy en Josas, France
    J Clin Microbiol 43:4654-8. 2005
    ..Biodiversity remains high in ulcerated mucosa. This argues against a pathogenic role of localized qualitative dysbiosis in CD-associated ulceration...
  6. ncbi Ineffectiveness of Lactobacillus johnsonii LA1 for prophylaxis of postoperative recurrence in Crohn's disease: a randomised, double blind, placebo controlled GETAID trial
    P Marteau
    Department Gastroenterology, Hopital Europeen Georges Pompidou, Paris, France
    Gut 55:842-7. 2006
    ..Bacteria are involved, and probiotics may modulate immune responses to the intestinal flora. Here we tested the probiotic strain Lactobacillus johnsonii LA1 in this setting...
  7. ncbi Temperature gradient gel electrophoresis of fecal 16S rRNA reveals active Escherichia coli in the microbiota of patients with ulcerative colitis
    H Sokol
    INRA, UEPSD, CR de Jouy-en-Josas, 78352 Jouy-en-Josas, France
    J Clin Microbiol 44:3172-7. 2006
    ..E. coli is more represented in the active microbiota of UC patients. The possible pathophysiological role of this difference remains to be determined...
  8. ncbi Alterations of the dominant faecal bacterial groups in patients with Crohn's disease of the colon
    P Seksik
    INRA, CR de Jouy-en-Josas, 78352 Jouy en Josas, France
    Gut 52:237-42. 2003
    ..Enterobacteria were observed significantly more frequently in CD than in health, and more than 30% of the dominant flora belonged to yet undefined phylogenetic groups...
  9. ncbi Review article: gut flora and inflammatory bowel disease
    P Marteau
    Département d Hépato Gastroentérologie, Hopital Europeen Georges Pompidou, Paris, France
    Aliment Pharmacol Ther 20:18-23. 2004
    ..The possibility of modifying the ecosystem using prebiotics or probiotics offers hope for new treatment developments, particularly in the prevention of relapse...
  10. ncbi Infliximab for refractory ulcerative colitis or indeterminate colitis: an open-label multicentre study
    J M Gornet
    Department of Gastroenterology, Hopital Saint Louis, Paris, France
    Aliment Pharmacol Ther 18:175-81. 2003
    ..The efficacy of infliximab in ulcerative colitis (UC) and indeterminate colitis has been poorly assessed and preliminary results are conflicting...
  11. ncbi Inflammatory bowel disease: what is new?
    P Marteau
    Department of Gastroenterology, Georges Pompidou European Hospital, Paris, and University of Paris V, France
    Endoscopy 36:130-6. 2004
    ....
  12. ncbi [Celiac disease in adults in 2006]
    P Marteau
    , APHP, , 2, rue Ambroise-Par, 75010 Paris, France
    Rev Med Interne 27:S59-60. 2006
  13. ncbi Nutritional advantages of probiotics and prebiotics
    P Marteau
    ISTNA INSERM U557 INRA U1125 EA CNAM 3200, Paris, France
    Br J Nutr 87:S153-7. 2002
    ..Positive trials have suggested preventive effects against intestinal colonization with specific gut pathogens including Clostridium difficile and Helicobacter pylori...
  14. ncbi Long-term outcome of patients with gastrointestinal bleeding of obscure origin explored by push enteroscopy
    B Landi
    Department of Hepatogastroenterology, Georges Pompidou European Hospital, Paris, France
    Endoscopy 34:355-9. 2002
    ..The aim of this study was to assess the rate of recurrent bleeding and its predictive factors in patients with gastrointestinal bleeding of obscure origin, after exploration by push enteroscopy...
  15. ncbi Bifidobacterium animalis strain DN-173 010 shortens the colonic transit time in healthy women: a double-blind, randomized, controlled study
    P Marteau
    Gastroenterology Department, European Hospital Georges Pompidou, Paris, France
    Aliment Pharmacol Ther 16:587-93. 2002
    ..A previous study has suggested that Bifidobacterium animalis DN-173 010 shortens the colonic transit time in women...
  16. ncbi Comparative study of bacterial groups within the human cecal and fecal microbiota
    P Marteau
    INSERM U 290, Paris, France
    Appl Environ Microbiol 67:4939-42. 2001
    ..Facultative anaerobes represented 25% of total bacteria in the cecum versus 1% in the feces...
  17. ncbi Tolerance to low-digestible carbohydrates: symptomatology and methods
    P Marteau
    Gastroenterology Department, European Hospital Georges Pompidou, Paris, France
    Br J Nutr 85:S17-21. 2001
    ..Double-blind, placebo-controlled studies are required to assess the subjective symptoms of intolerance, and the experimental conditions may influence the results...
  18. ncbi [Digestive and nutritional management of adults with cystic fibrosis]
    P Marteau
    Service de Gastroenterologie, Hopital Europeen Georges Pompidou, Paris
    Rev Mal Respir 17:785-97. 2000
    ....
  19. ncbi Inflammatory bowel disease
    P Marteau
    Dept of Gastroenterology, Laennec Hospital, Assistance Publique des Hopitaux de Paris, and University of Paris V, France
    Endoscopy 32:131-7. 2000
    ....
  20. ncbi Push enteroscopy in celiac sprue and refractory sprue
    C Cellier
    Department of Hepato Gastroenterology, Laennec Hospital and Necker Hospital, Assistance Publique Hôpitaux de Paris and Université René Descartes, Paris, France
    Gastrointest Endosc 50:613-7. 1999
    ..The aim of this study was to determine in patients with sprue whether jejunal endoscopy improves the diagnostic yield or provides information that may modify management, when compared with evaluation limited to the duodenum...
  21. ncbi Foetal outcome in women with inflammatory bowel disease treated during pregnancy with oral mesalazine microgranules
    P Marteau
    Service d Hepato Gastroenterologie, Hopital Laennec, Paris, France
    Aliment Pharmacol Ther 12:1101-8. 1998
    ..Little information is available about the safety of high doses of mesalazine during pregnancy...
  22. ncbi Highlighting new phylogenetic specificities of Crohn's disease microbiota
    S Mondot
    UMR1319 MICALIS, INRA, Domaine de Vilvert, 78350 Jouy en Josas, France
    Inflamm Bowel Dis 17:185-92. 2011
    ..Recent studies suggest that gastrointestinal (GI) microbes play a part in the pathogenesis of Crohn's disease (CD)...
  23. ncbi [MR imaging of ano-perineal suppurations]
    C A Cuenod
    Service de Radiologie, Hopital Europeen Georges Pompidou, 20 rue Leblanc, 75015 Paris
    J Radiol 84:516-28. 2003
    ....
  24. ncbi Probiotics and intestinal health effects: a clinical perspective
    P Marteau
    Gastroenterology Department, Hopital Europeen Georges Pompidou, Assistance Publique des Hopitaux de Paris, 20 rue Leblanc, 75908 CEDEX 15, France
    Br J Nutr 88:S51-7. 2002
    ..We also analysed the recent randomised controlled trials performed in patients with Clostridium difficile or Helicobacter pylori, inflammatory bowel disease, irritable bowel syndrome, non-ulcer dyspepsia and colon cancer...
  25. ncbi Mesalamine in the treatment of active Crohn's disease
    Axel Dignass
    Gastroenterology 128:245-6; author reply 246. 2005
  26. ncbi A double blind randomized controlled trial of a probiotic combination in 100 patients with irritable bowel syndrome
    S Drouault-Holowacz
    PiLeJe, 37, quai de Grenelle, bâtiment Pollux, 75738 Paris Cedex 15, France
    Gastroenterol Clin Biol 32:147-52. 2008
    ..The purpose of this study was to evaluate the effects of a probiotic combination on symptoms in patients with irritable bowel syndrome (IBS)...
  27. ncbi Probiotics, prebiotics, synbiotics: ecological treatment for inflammatory bowel disease?
    P Marteau
    Gut 55:1692-3. 2006
  28. ncbi Safety of probiotics that contain lactobacilli or bifidobacteria
    S P Borriello
    Central Public Health Laboratory, London, United Kingdom
    Clin Infect Dis 36:775-80. 2003
    ..Vigilance regarding the detection of possible rare cases of infection due to probiotics should be maintained, and isolates should be sent to reference centers for molecular characterization and confirmation...
  29. ncbi European evidence based consensus on the diagnosis and management of Crohn's disease: current management
    S P L Travis
    John Radcliffe Hospital, Oxford OX3 9DU, UK
    Gut 55:i16-35. 2006
    ..The third section on special situations in Crohn's disease includes postoperative recurrence, fistulating disease, paediatrics, pregnancy, psychosomatics, extraintestinal manifestations, and alternative therapy for Crohn's disease...
  30. ncbi Tioguanine in patients with Crohn's disease intolerant or resistant to azathioprine/mercaptopurine
    B Bonaz
    Département d Hépato Gastroentérologie, CHU de Grenoble, France
    Aliment Pharmacol Ther 18:401-8. 2003
    ..Tioguanine (TG) is an antimetabolite which may be regarded as an alternative to azathioprine (AZA)/mercaptopurine (MP) in patients with inflammatory bowel diseases...
  31. ncbi [Endoscopic treatment of lower intestinal haemorrhage of diverticular origin]
    E Cuillerier
    Gastroenterol Clin Biol 27:558-9. 2003
  32. ncbi Decrease in factor V activity: a new adverse effect of purine analogs in inflammatory bowel diseases?
    S Poupeney
    Inflamm Bowel Dis 14:1024-5. 2008
  33. ncbi Dysbiosis in inflammatory bowel disease: a role for bacteriophages?
    P Lepage
    Gut 57:424-5. 2008
  34. ncbi Mycobacterium avium duodenal infection mimicking Whipple's disease in a patient with AIDS
    X Dray
    , APHP, , , Paris, France
    Endoscopy 39:E296-7. 2007
  35. ncbi Nodular regenerative hyperplasia in patients with inflammatory bowel disease treated with azathioprine
    G Vernier Massouille
    Department of Hepato Gastroenterology, Hopital Claude Huriez, CH et U de Lille, France
    Gut 56:1404-9. 2007
    ....
  36. ncbi Antioxidant effects of metronidazole in colonic tissue
    M A Pelissier
    Laboratoire de Biologie, EA 3199, Conservatoire National des Arts et Metiers, 2 rue Conté, 75003 Paris, France
    Dig Dis Sci 52:40-4. 2007
    ..MTZ reduced significantly the colonic oxidative damage to proteins without any side effect in the liver. This is the first evidence of an antioxidant effect of MTZ on oxidative protein damage in the colon under physiologic conditions...
  37. ncbi Review article: the role of bacteria in onset and perpetuation of inflammatory bowel disease
    P Seksik
    , , AP-HP, Paris, France
    Aliment Pharmacol Ther 24:11-8. 2006
    ..Studies searching for a generalized or localized dysbiosis in IBD are discussed, as well as those trying to identify bacterial molecules and receptors, which may be implicated in triggering the inflammatory process...
  38. ncbi Malnutrition in adults with cystic fibrosis
    X Dray
    , , Paris, France
    Eur J Clin Nutr 59:152-4. 2005
    ..6% of patients with a mild genotype (P<0.001). CONCLUSION: Malnutrition remains frequent in adults with CF except in patients presenting with a mild CFTR genotype (leading to a mild phenotype and to later diagnosis)...